Unser Referententeam vor Ort

14 Experten präsentieren die aktuellen Studienergebnisse

  • Prof. Peter Borchmann
    Prof. Peter Borchmann Uniklinik Köln
    Prof. Peter Borchmann

    Non-Hodgkin-Lymphome: DLBCL und CLL

    Consultancy: Celgene, Novartis, Roche, Takeda
    Research Funding: Celgene, Novartis, Takeda
    Honoraria: Amgen, Novartis, Roche, Takeda
    Patents and Royalties: not applicable
    Membership on an entity’s Board of Directors or advisory committees: not applicable
    Discussion of off-label drug use: not applicable

  • Prof. Tim Henrik Brümmendorf
    Prof. Tim Henrik Brümmendorf Uniklinik RWTH Aachen
    Prof. Tim Henrik Brümmendorf

    Chronische Myeloische Leukämie:
    Therapieoptionen bei Resistenz oder Intoleranz

    Consultancy: Ariad, Novartis, Pfizer
    Research Funding: Novartis, Pfizer
    Honoraria: not applicable
    Patents and Royalties: Combination of Imatinib with Hypusination Inhibitors (Novartis)
    Membership on an entity’s Board of Directors or advisory committees: not applicable
    Discussion of off-label drug use: if off label drug use is discussed, it will be indicated appropriately

  • Prof. Holger Cario
    Prof. Holger Cario Universitätsklinikum Ulm
    Prof. Holger Cario

    Hämoglobinopathien und Eisenüberladung

    Consultancy: not applicable
    Research Funding: not applicable
    Honoraria: Novartis, ApoPharma
    Patents and Royalties: not applicable
    Membership on an entity’s Board of Directors or advisory committees: Novartis
    Discussion of off-label drug use: not applicable

  • Prof. Martin Dreyling
    Prof. Martin Dreyling Klinikum der Universität München
    Prof. Martin Dreyling

    Non-Hodgkin-Lymphome: FL, MCL und andere

    Scientific Advisory Board: Bayer, Celgene, Gilead, Janssen, Pfizer
    Research Funding (Institution): Celgene, Janssen, Mundipharma, Pfizer, Roche
    Honoraria: Celgene, Gilead, Janssen, Pfizer, Roche
    Patents and Royalties: not applicable
    Membership on an entity’s Board of Directors or advisory committees: not applicable
    Discussion of off-label drug use: not applicable

  • Prof. Andreas Engert
    Prof. Andreas Engert Uniklinik Köln
    Prof. Andreas Engert

    Hodgkin-Lymphom

    Consultancy: Takeda/Millennium, Affimed
    Research Funding: Takeda/Millennium, BMS, Affimed
    Honoraria: Takeda/Millennium
    Patents and Royalties: not applicable
    Membership on an entity’s Board of Directors or advisory committees: Takeda/Millennium, Novartis
    Discussion of off-label drug use: yes

  • Dr. Nicola Gökbuget
    Dr. Nicola Gökbuget Universitätsklinikum Frankfurt am Main
    Dr. Nicola Gökbuget

    Akute Lymphatische Leukämie

    Consultancy: AMGEN, Jazz Pharmaceuticals, Gilead, Erytech, Celgene, Kite, Baxalta
    Research Funding: AMGEN, Jazz Pharmaceuticals, Novartis
    Invited Speaker: AMGEN, Novartis, Pfizer, Jazz Pharmaceuticals, Baxalta
    Membership on an entity’s Board of Directors or advisory committees: not applicable
    Discussion of off-label drug use: not applicable

  • Prof. Hartmut Goldschmidt
    Prof. Hartmut Goldschmidt Universitätsklinikum Heidelberg
    Prof. Hartmut Goldschmidt

    Multiples Myelom

    Research Support (Institutions): Celgene, Janssen, Chugai, Novartis, BMS
    Advisory Boards (Institutions): Janssen, Celgene, Novartis, Amgen Takeda, BMS
    Honoraria: Celgene, Janssen, Novartis, Chugai, BMS

  • Prof. Martin Griesshammer
    Prof. Martin Griesshammer Johannes Wesling Universitätsklinikum, Minden
    Prof. Martin Griesshammer

    Therapie der klassischen Myeloproliferativen Neoplasien

    Consultancy: not applicable
    Research Funding: not applicable
    Honoraria: Amgen, Janssen, Novartis, Roche, Shire, AOP orphan
    Patents and Royalties: not applicable
    Membership on an entity’s Board of Directors or advisory committees: not applicable
    Discussion of off-label drug use: not applicable

  • Prof. Wolf-Karsten Hofmann
    Prof. Wolf-Karsten Hofmann Universitätsmedizin Mannheim
    Prof. Wolf-Karsten Hofmann

    Myelodysplastisches Syndrom

    Consultancy: not applicable
    Research Funding: Celgene, Novartis
    Honoraria: Celgene, Novartis
    Patents and Royalties: not applicable
    Membership on an entity’s Board of Directors or advisory committees: not applicable
    Discussion of off-label drug use: not applicable

  • Dr. Mohamad Jawhar
    Dr. Mohamad Jawhar Universitätsmedizin Mannheim
    Dr. Mohamad Jawhar

    MPN Diagnostik, seltene MPN und AdvSM

    Consultancy: not applicable
    Research Funding: not applicable
    Honoraria: Novartis
    Patents and Royalties: not applicable
    Membership on an entity’s Board of Directors or advisory committees: not applicable
    Discussion of off-label drug use: not applicable

  • Prof. Nicolaus Kröger
    Prof. Nicolaus Kröger Universitätsklinikum Hamburg-Eppendorf
    Prof. Nicolaus Kröger

    Stammzelltransplantation

    Consultancy: Medac
    Equity Ownership: not applicable
    Research Funding: Neovii, Celgene , Riemser , Novartis
    Honoraria: Neovii, Novartis, Riemser
    Patents and Royalties: not applicable
    Membership on an entity’s Board of Directors or advisory committees: not applicable
    Discussion of off-label drug use: not applicable

  • Prof. Axel Matzdorff
    Prof. Axel Matzdorff Asklepios Klinikum Uckermark
    Prof. Axel Matzdorff

    Immunthrombozytopenie

    Consultancy: AMGEN, GlaxoSmithKline, Leo Pharma, Boehringer Ingelheim
    Equity Ownership: Bayer, Roche
    Research Funding: Leo Pharma
    Honoraria: Amgen, Aspen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Chugai, Gilead, GlaxoSmithKline„ Janssen, Leo Pharma, Lilly, MSD, Mundipharma, Novartis, Pfizer, Roche, Sanofi
    Patents and Royalties: not applicable
    Membership on an entity’s Board of Directors or advisory committees: not applicable
    Discussion of off-label drug use: yes

  • Prof. Susanne Saußele
    Prof. Susanne Saußele Universitätsmedizin Mannheim
    Prof. Susanne Saußele

    Chronische Myeloische Leukämie: Erstlinientherapie und TFR

    Consultancy: not applicable
    Research Funding: BMS, Novartis
    Honoraria: BMS, Ariad (Incyte), Novartis, Pfizer
    Patents and Royalties: not applicable
    Membership on an entity’s Board of Directors or advisory committees: not applicable
    Discussion of off-label drug use: not applicable

  • Prof. Richard Schlenk
    Prof. Richard Schlenk National Tumor Center, Heidelberg
    Prof. Richard Schlenk

    Akute Myeloische Leukämie

    Consultancy: Daiichi, Novartis, Pfizer
    Research Funding: AstraZeneca, Novartis, PharmaMar, Pfizer
    Honoraria: Novartis, Pfizer
    Patents and Royalties: not applicable
    Membership on an entity’s Board of Directors or advisory committees: Daiichi-Quantum-F
    Discussion of off-label drug use: not applicable